El Protocolo Banerji
Un nuevotumores métodocerebrales para el tratamiento de con Ruda y Fosfato Tricálcico
Prasanta Banerji
Pratip Banerji
Fundación de Investigación Homeopática Prasanta Banerji (PBHR)
Los Drs. Prasanta y Pratip Banerji en la conferencia CCC2000 (Comprehensive Cancer Care) de medicina de cuerpo y mente en Arlington, EE. UU.
Prefacio
El fundador de la Homeopatía, Samuel Christian Friedrich Hahnemann, publica en 1796 los resultados de sus investigaciones en un artículo titulado “Ensayo sobre un nuevo principio para conocer el poder curativo de los fármacos”. En él expone el principio
fundamental de la Homeopatía, afirmando que “Toda sustancia farmacológicamente activa, provoca en el individuo sano y sensible un conjunto de síntomas característicos de dicha sustancia, cuanto más fuerte sea el medicamento, más violenta y acentuada será la enfermedad provocada. Deberíamos imitar a la naturaleza, que, en ocasiones, cura una enfermedad crónica por medio de otra enfermedad. Por eso debemos recetar, para la enfermedad que queremos curar, especialmente si se trata de
una enfermedad crónica, un fármaco que tenga el poder de provocar otra enfermedad artificial tan similar como sea posible a la que se quiere curar. Lo similar se cura con lo similar.” En Homeopatía, la dilución de un medicamento se lleva a cabo bien dentro de los límites aceptados por norma general (dilución molecular) o fuera de los mismos (límites ultramoleculares). Este proceso se consigue mediante la sucusión y/o trituración del principio activo en cada fase de la dilución.
La Homeopatía de Hahnemann no posee un remedio específico para cada enfermedad pero sí para cada enfermo. Diez casos de tuberculosis pueden necesitar diez medicamentos diferentes, mientras que diez enfermedades diferentes pueden precisar el mismo medicamento, siempre que sus síntomas sean más o menos similares. Este enfoque de tratamiento de pacientes teniendo en cuenta solamente sus síntomas es fundamentalmente indispensable de cara a aquellos síntomas crónicos que no se corresponden con una naturaleza fija y que varían dependiendo de cada paciente. Un mismo fármaco no tiene porque ser útil para cada caso.
En general, cuando un homeópata examina a un paciente sólo tiene en cuenta algunos medicamentos para su tratamiento. Este pequeño grupo sustancias producen síntomas similares. Por último, sólo se selecciona uno de ellos como consecuencia de la experiencia práctica.
Nosotros hemos refrendado y propagado la idea de utilizar un medicamento homeopático específico para combatir una enfermedad teniendo en cuenta sus síntomas. Hoy en día, el tipo de tratamiento se modifica rigurosamente al tener en cuenta los datos de diagnóstico de laboratorio que permiten seleccionar un medicamento específico para combatir una enfermedad particular. En este nuevo método de tratamiento no nos apoyamos en la máxima de Hahnemann: "Único, simple y mínimo.”
En este nuevo método de tratamiento no nos importa prescribir mezclas de remedios o repetir de manera asidua el uso de los mismos cuando sea necesario, sin embargo, la Homeopatía convencional nunca sigue este planteamiento. El uso de la combinación de dos medicamentos se realiza de manera significativa y está basado en años de experimentos clínicos y observaciones llevadas a cabo por nosotros mismos. Los medicamentos se combinan para conseguir una serie de ventajas especiales de cara al tratamiento, de ahí que se pueda controlar un posible empeoramiento producido por los fármacos, que los efectos secundarios de los mismos puedan mitigarse y que pueda garantizarse una rápida recuperación en un tiempo más breve. En la actualidad, nuestra Fundación lleva a cabo un trabajo de investigación en colaboración con investigadores del MD Anderson Cancer Center acerca de la acción de las medicinas homeopáticas sobre varios tipos de células cancerígenas, por ejemplo, tumores cerebrales, cáncer de mama, etc. Los NIH (Institutos Nacionales de la Salud) de EE. UU se han interesado en nuestra investigación sobre varios tipos de cáncer y nos han solicitado la realización de registros que documenten nuestros exitosos resultados. Para ello hemos presentado ante el Centro Nacional para la Medicina Complementaria y Alternativa (NCCAM) y el Instituto Nacional del Cáncer (NCI) de los NIH el programa “Best Case Series” sobre el cáncer. En la actualidad, el NCI de EE. UU está creando un
“Estudio observacional de las posibles consecuencias para el Carcinoma Broncogénico” en nuestra clínica en India, con vistas a alcanzar un protocolo para el tratamiento de esta enfermedad que les permita preparar el terreno para realizar ensayos clínicos en EE. UU. El progreso científico nos exige realizar cada vez más experimentos con medicamentos en unsegran número pacientes conservar todos los documentos observacionales que deriven de los mismos.así Decomo hecho, hemos reunido una gran cantidad de datos observacionales basados en nuestra experiencia, que nos han dado seguridad a la hora de recetar dosis frecuentes y, en ocasiones, para mezclar o alternar medicamentos, siempre que fuese necesario. En las últimas tres décadas hemos tratado a miles de pacientes con cáncer. Mostraremos algunos resultados de nuestro tratamiento conseguidos en los últimos tiempos. Este es el resultado general del tratamiento de más de 17.324 pacientes con cáncer desde 1990 a 2005 realizado en nuestra clínica. Estos gráficos muestran que en el 19% de los casos hubo una regresión completa de los tumores, muy significativa desde nuestro punto de vista. En el 21% de los casos los tumores permanecieron estacionarios o experimentaron una mejoría después del tratamiento.
Resultados del tratamiento de 17.324 casos de tumor maligno (1990 – 2005)
34% Agravado 19% Regresión Completa
26% Interrumpido 21% Estacionario
En nuestra Fundación de Investigación, realizamos un tratamiento exitoso de los tumores cerebrales con medicamentos homeopáticos. Gracias a nuestra amplia experiencia clínica pudimos ofrecer ayuda a un gran porcentaje de pacientes, algunos de los cuales evidenciaron una regresión completa posteriormente. En el tratamiento de estos casos se empleó la Ruta 6 y el Fosfato Tricálcio. A través de la observación durante los últimos 30 años, se ha podido confirmar que estos medicamentos tienen el poder de reducir y curar lesiones ocupantes de espacio
(LOE) intracraneal. En el MD Anderson Cancer Center de Houston se han llevado a cabo de manera exitosa varios experimentos in vitro utilizando esta combinación de medicamentos y ya se ha publicado un artículo científico en esta línea.
Algunos de los primeros casos de tumor cerebral tratados de manera exitosa:
Consideraremos dos casos que hemos tratado haciendo uso de todos los informes médicos y de toda la información documentada durante años, incluyendo TAC (Tomografía Axial Computarizada) antes y después del tratamiento.
F.Y., mujer de 27 años de edad cumplidos en diciembre de 1990, padecía dolores de cabeza esporádicos desde 1986. El 17 de diciembre de 1990 sufrió un fuerte dolor de cabeza, más acentuado en el hemisferio izquierdo. El 29 de diciembre de 1990, cuando acudió a nuestra clínica para someterse a tratamiento, los dolores iban acompañados de mareos y visión borrosa. En su historial clínico quedó registrado que la paciente manifestaba visión borrosa, dolor y debilidad en la parte derecha. Tras realizarse un TAC cerebral el 25.12.1990, se dedujo: "La anomalía más importante es la presencia de una masa bien delimitada con valores de atenuación de tipo mixto (hipo e hiperdensa) en la región suprasillar e intrasillar que produce una notable dilatación de la silla turca ligeramente superior en el lado izquierdo. Esta gran masa mide como máximo 2’2 cms en AP, 3’54 cms en lateral y 3’37 cms en vertical, ¿craneofaringioma? ¿macroadenoma pituitario?
TAC cerebral con fecha 25.12.1990
Después de someterse a nuestro tratamiento con Ruta 6 y Fosfato Tricálcico, la visión borrosa mejoró a partir del primer mes desde el comienzo del tratamiento y hoy
en día ha recuperado totalmente la visión. El paciente se recuperó completamente del dolor y de la debilidad que sufría en el brazo derecho. En la actualidad es una persona sana y normal que disfruta de la vida.
El TAC cerebral realizado 27 de abril de 1992 reveló: “Caso complementario de masa intrasillar bastante grande con predominio de extensión suprasillar que, en la actualidad, evidencia una desaparición completa dejando atrás un aspecto normal de la glándula pituitaria y de la cisterna suprasillar desde el último escáner realizado el 25 de diciembre de 1990.
TAC cerebral con fecha 27.04.1992
El marido de la paciente no visitó recientemente y nos informó de su buen estado de salud. A.A., hombre casado de 60 años, acudió a nuestra clínica el 03.08.2004 con síntomas de debilidad gradual y progresiva en la parte derecha de su cuerpo y extremidades, insomnio, irritabilidad y enojo fácil desde hacía 2 meses. Antes de acudir a nuestra clínica se le …”Glioma realizó un TAC cerebral con fecha 28.07.2004 ….. Impresión de diagnóstico multicéntrico….”
TAC cerebral con fecha 28.07.2004
La biopsia estereotáctica realizada el 29.01.2004 ….. desde la cápsula interna derecha…….. “Neoplasia de alto grado….. Glioma.” El informe del Hospital del Colegio Médico Cristiano (CMC) de Vellore del 29.07.2004…. hace pesar en “¿Corpus Collosum (cuerpo calloso) y neoplasia glial de alto grado a nivel periventricular del lado parietal derecho?”
Diapositiva de una histopatología
Tras a nuestro tratamiento dosisHasta diarias de Ruta 6 y Fosfato todossometerse sus síntomas desaparecieron trascon 7-8dos meses. ahora, el paciente llevaTricálcio una vida normal y sin problemas aunque todavía continúa en tratamiento.
El TAC cerebral (Estudio sencillo y de contraste) realizado el 16.04.2005 reflejó “…. Áreas hipodensas y calcinosis en la región frontal derecha. Al contrastarlo con el anterior TAC cerebral del 25.07.2004 la masa casi ha desparecido.”
Durante el tratamiento se produjo una reaparición de tumores.
TAC cerebral con fecha 16.04.2005
Cómo actúan la Ruda y el Fosfato Cálcico
La rutina, componente activo de la Ruda, es conocida por sus propiedades antinflamatorias y antioxidantes y también por reducir el daño oxidativo en modelos de experimentación con roedores. Además, la Ruda también es conocida por proteger al ADN contra la ruptura de sus hilos y por prevenir la mutagenesis. El Fosfato Cálcico activa la fosfolipasa, que cliva el fosfatidil inositol difosfato, una molécula rodeada por una membrana que activa la proteína quinasa C.
Dibujo de la planta Ruta graveolens
Resumen del artículo publicado en la Revista Internacional de Oncología nº 23: 975-982, 2003
“El uso de la quimioterapia convencional en el tratamiento de pacientes con tumores malignos puede afectar de manera negativa a las células normales." Las células hematopoyéticas de la médula ósea son las más afectadas. Por consiguiente, es necesario hallar agentes alternativos capaces de destruir las células cancerígenas pero que tengan unos efectos mínimos sobre las células normales. Examinamos la actividad destructiva de células cancerígenas del cerebro de un medicamento homeopático, la Ruda, aislada de una planta, Ruta graveolens. Utilizamos distintas concentraciones de Ruda en combinación con CO3(PO4)2 para el tratamiento in vitro del cáncer de cerebro humano y de las células de leucemia HL-60, de las células normales de linfocitos B y de las células de melanoma murino. Se trató con Ruta 6 y CO3(PO4)2 a quince pacientes con tumores intracraneales. De estos 15 pacientes, 6 de los 7 que padecían glioma experimentaron una regresión completa de los tumores. Con el fin de comprender el posible mecanismo de destrucción celular y empleando técnicas de la citogenética molecular y convencional, se examinaron los linfocitos normales de la sangre humana, las células de linfocitos B y las células cancerígenas del cerebro tratadas con Ruda in vitro en busca de la dinámica de la región telomérica, catástrofe mitótica y apoptosis. Ambos resultados, tanto in vivo como in vitro, mostraron una inducción de
las vías de señalización de supervivencia en linfocitos normales y una inducción de las vías de señalización de muerte en las células cancerígenas del cerebro. El proceso de destrucción de las células cancerígenas se inició por medo de la erosión telomérica y se completó a través de episodios de catástrofe mitótica. Pensamos que la Ruda en combinación con CO3(PO4)2 puede ser útil para el tratamiento eficaz del cáncer de cerebro, en especial el glioma.”
Perspectiva actual de casos de tumor cerebral tratados con nuestros medicamentos:
La Ruda y el Fosfato Cálcico pueden prevenir la reaparición de tumores cerebrales.
Resumen:
A pesar de la existencia de muchas terapias alternativas y convencionales, la reaparición de tumores cerebrales tras la cirugía, la radiación o la quimioterapia es un problema común. Últimamente, nuestro tratamiento del tumor cerebral con Ruta 6 y Fosfato Tricálcico está adquiriendo popularidad en India y la mayoría de estos pacientes utilizan nuestro tratamiento sin necesidad de someterse a ningún otro tipo de intervención convencional. Sin embargo, hoy en día, nuestro tratamiento se utiliza en otros países, fundamentalmente para prevenir recidivas. Hemos analizado documentos de 147 casos disponibles hasta la fecha (76 casos en India, 44 casos en EE. UU. y 27 en otros países incluyendo Reino Unido, Canadá, España, Italia, Suecia, Australia, Nueva Zelanda, los Países Bajos, Turquía, Israel, Malasia, Pakistán, etc.) en los que se han empleado nuestros medicamentos sólo para prevenir recidivas sin hacer uso simultáneo de ninguna otra terapia convencional. En el 66,74% de los casos, dicho análisis evidenció que nuestros medicamentos desempeñan un papel definitivo en la prevención de recidivas de tumores cerebrales. En cuanto al oligodendroglioma la prevención de recidivas fue extraordinaria, sin embargo, en gliomas del tronco cerebral ésta fue relativamente menor.
Introducción:
La recidiva de tumores cerebrales es un fenómeno común y a pesar de que se han encontrado diferencias en relación a la reaparición en distintos tipos de tumores cerebrales, estas son muy elevadas, teniendo en cuenta aspecto global.
Aunque la administración de quimioterapia, principalmente con temozolomida y/o de radioterapia, es eficaz de cara a la prevención, por lo menos en cierta medida, hasta ahora no existe un cambio significativo del punto de vista y la mayoría de los pacientes con tumor cerebral mueren incluso después de haber utilizado todos los medios posibles para evitar su reaparición. En 2000, se diagnosticaron, en todo el mundo, aproximadamente 176.000 nuevos casos de tumor cerebral y otros tumores del sistema nervioso central (SNC), con una mortalidad aproximada de 128.000 (Parkin et al, 2000). En 2006, se han registrado en EE. UU., aproximadamente, 18.820 nuevos casos y 12.820 muertes como
consecuencia de tumores cerebrales y otros tumores del sistema nervioso (American Cancer Society: Cancer Facts and Figures 2006. Atlanta, Ga: American Cancer Society, 2006. Last accessed August 7, 2006). Los tumores cerebrales representaron entre el 85% y 90% del total de tumores primarios del sistema nervioso central (Levin et al, 2001) y, entre 1996 y 2000, la base de datos del programa Surveillance, Epidemiology and End Results (SEER) indicó que el índice de tumores primarios invasivos del sistema nervioso central en EE. UU. es de 6,6 por cada 100.000 personas al año, con una mortalidad anual aproximada de 4,7 por cada 100.000 personas. En la actualidad, un número significativo de pacientes con tumor cerebral sufren recidivas. Por ello, llevamos trabajando durante un periodo relativamente largo con el fin de descubrir algún medio a través del cual podamos prevenir la reaparición tumoral. Nuestro prolongado afán de búsqueda de alguna sustancia química que pudieran servir de ayuda en este proceso nos condujo a la Ruta 6 y el Fosfato Tricálcico. En este artículo intentaremos ofrecer algunos detalles acerca de nuestro trabajo de investigación, llevado a cabo .con estas sustancias, para la prevención de recidivas de tumores cerebrales malignos
Materiales y Métodos:
Pacientes con tumor cerebral: A pesar de que existen muchos pacientes con tumor cerebral en todo el mundo, es imposible probar en ellos nuevos medicamentos, salvo, excepcionalmente, en algunos ensayos clínicos de Fase I y II, teniendo al alcance todas las infraestructuras preventivas que nos permitan controlar cualquier efecto adverso que pudiera surgir en el momento o con posterioridad. Por ello, buscamos cualquier medicamento adecuado mediante el análisis de cientos de extractos diferentes utilizados en la farmacopea homeopática que no hubieran sido sometidos a un examen apropiado tras la muerte, hace 200 años, de su iniciador, el Dr.
Samuel Christian Friedrich Hahanemann. Estas sustancias químicas son completamente inofensivas cuando se diluyen, sin embargo, existen pruebas documentadas que demuestran que un incremento de la dilución produce efectos biológicos positivos (Banerji and Banerji, 2001, Sen Pathak et al, 2003). Ya que ambos autores se dedican a la práctica médica de estos medicamentos homeopáticos, les fue más sencillo seleccionar medicamentos para combatir tumores cerebrales de entre miríadas de preparaciones. Con anterioridad a sus publicaciones (Banerji and Banerji, 2001), se desconocía que la Ruta 6 y el Fosfato Tricálcico eran eficaces contra los tumores cerebrales. Tras la publicación de nuestro primer trabajo (Banerji and Banerji, 2001, Sen Pathak et al, 2003), miles de personas que padecían tumor cerebral acudieron, no sólo a nuestras clínicas privadas sino también fuera de India, donde personas interesadas comenzaron a ofrecer ayuda a pacientes con tumor cerebral para que se beneficiaran de nuestro tratamiento específico contra dichos tumores (Fundación del Tumor Cerebral, EE. UU.).
Debido a que una multitud de pacientes (cifra que asciende a algunos miles) ya se está sometiendo al tratamiento con Ruta 6 y Fosfato Tricálcico y ya que un número significativo se ha beneficiado del mismo, dato que se ha observado no sólo en nuestro centro de India sino también en otras partes del mundo, ahora estamos interesados en investigar las características preventivas de estos medicamentos para combatir la reaparición de tumores cerebrales tras la cirugía tanto en India como en otros países: Reino Unido, Canadá, España, Italia, Suecia, Australia, Nueva Zelanda, Países Bajos, Turquía, Israel, Malasia, Pakistán, etc. (ver tabla 1 y gráfico 1).
Tabla 1: País
Nº.depacientestratados para prevenir recidivas de tumor cerebral
India
76
EE. UU.
64
Reino Unido, Canadá,
27
España, Italia, Suecia, Australia, Nueva Zelanda, Países Bajos, Turquía, Israel, Malasia, Pakistán, etc.
Total
147
Gráfico 1: Nº de casos de tumor cerebral en otros países.
Nº de casos
El gobierno indio aprobó el uso de estos medicamentos y estamos autorizados a emplearlos en el tratamiento de estos pacientes, sin embargo, seguimos el protocolo estándar del consentimiento del paciente, la autorización del comité ético, la revisión de los pacientes por parte de oncólogos eminentes de la ciudad, los seguimientos clínicos adecuados siguiendo criterios de inclusión y exclusión y el control apropiado de los casos adversos. Fuera de India existen algunos centros de apoyo (Fundación del Tumor Cerebral), muchos de los cuales se pusieron en contacto con nosotros y siguieron el programa de tratamiento con todos los servicios de apoyo médico y de investigación ofrecidos por los doctores del país de cada paciente.
De todos estos pacientes, 57 (38,8%) padecían astrocitoma y otros gliomas, 28 (19,0%) padecían meningioma, 20 (13,6%) padecían adenoma pituitario y 42 (28,6%) padecían otras variedades de tumor.
64 pacientes (43,5%) presentaron grado IV, 36 (24,5%) grado III y 47 (32,0%) grado II. Ningún paciente p
Los medicamentos:
Tal y como se menciona anteriormente, hemos empleado dos sustancias químicas, Ruta 6 y Fosfato Tricálcico de acuerdo con la farmacopea homeopática británica e india. Estas sustancias se obtuvieron directamente de Holistic Remedies Pvt. Ltd, Mumbai, India (en colaboración con Bioforce A.G., Suiza).
Dosis:
1. Ruta graveolens 6c, una dosis = 2 gotas en 1 cucharadita de agua potable, dos dosis diarias. 2. Calcarea Phosphorica 3x, una dosis = 2 comprimidos (gránulos), dos dosis diarias.
Seguimiento:
Desde el comienzo del tratamiento se realizó un seguimiento de al menos un año a todos los pacientes.
Gráfico 2: Resultado del tratamiento del tumor cerebral con el Protocolo Banerji en varios países.
India EE. UU Otros países
Sin recidiva Recidiva Sin valoración
Perspectiva médica en India:
En India, nosotros tratamos de manera directa a todos los pacientes después de haber sido sometidos a cirugía y a ninguno de ellos se les administró quimioterapia ni radioterapia. El resultado de nuestro tratamiento en pacientes indios se puede observar en la Tabla 2 (ver también Gráfico 2). En el 78,9% de los pacientes no hubo recidiva, en el 13,2% de los pacientes se produjo una recidiva y en el 7,9% de los casos no se pudo ofrecer una valoración exacta.
Tabla 2: casos tratados en India (N=76) Sin recidiva Recidiva Sinvaloraciónexacta
78,9% 13,2% 7,9%
En aquellos pacientes que padecían oligodendroglioma, el papel preventivo de estos medicamentos más eficaz (100%) que en pacientes con gliobastoma multiforme (GBM) (66,7%) y, en rasgos generales, observamos que 60 pacientes (78,9%) de 76 se beneficiaron de nuestro tratamiento.
Perspectiva médica en EE. UU.:
En EE. UU. tuvimos a nuestra disposición la información así como todos los documentos referentes de 44 pacientes con características similares. El resultado de nuestro tratamiento en pacientes con tumor cerebral en EE. UU. puede observarse en la Tabla 3 (ver también Gráfico 2). No se observó recidiva en el 63,6% de los casos, el 22,2% de los pacientes sufrió una recidiva y en el 18,2% de los casos no se pudo ofrecer una valoración exacta. En rasgos generales, observamos que el 63,6% de los pacientes se benefició de nuestro tratamiento.
Tabla 3: casos tratados en EE. UU. (N=44) Sin recidiva Recidiva Sinvaloraciónexacta
78,9% 22,2% 18,2%
Pacientes de otros países:
Contamos con registros de 27 pacientes de otros países (Tabla 1). El resultado de nuestro tratamiento en pacientes con tumor cerebral puede observarse en la Tabla 4 (ver también Gráfico 2). El 37,0% de los pacientes no sufrió ninguna recidiva, el 22,2% sufrió una recidiva y en el 40,7% de los casos no se pudo ofrecer una valoración exacta. En general, observamos que un 37,0% de los pacientes se benefició de nuestro tratamiento.
Tabla 4: Casos tratados en otros países (N=27) Sin recidiva Recidiva Sinvaloraciónexacta
37,0% 22,2% 40,7%
Por lo tanto, de un total de 147 pacientes observamos que 98 (66,74%) se beneficiaron de nuestro tratamiento)
Gráfico 3: Resultado del tratamiento de tumor cerebral siguiendo el Protocolo Banerji (Nº total de casos)
Sin valoración Recidiva Sin recidiva
Discusión:
El principal problema al que nos enfrentamos en todo el mundo es a una posible recidiva del tumor cerebral tras la cirugía, y por el momento, no hay ninguna solución eficaz a la vista. Nuestro intento por solucionar este problema fue muy esperanzador con una índice de beneficio ante la prevención de recidivas del 66.74%. Sin embargo, cuando comparamos los resultados de los pacientes sometidos a nuestro tratamiento en distintas áreas geográficas, nos encontramos con que obtenemos mejores resultados en India y en EE. UU. que en otros países. Es difícil determinar una razón exacta que explique este dato, si bien es cierto que tanto en India como en EE. UU. contamos con tratamientos y centros de apoyo que no existen otros países en los que los pacientes sometidos a nuestro tratamiento dependen, por lo general, solamente de consultas online. Por ello, es posible que tampoco puedan seguir el protocolo adecuado ni tener acceso a los medicamentos apropiados de acuerdo con la farmacopea británica o india, que, por el contrario, pueden conseguirse con facilidad en India y EE. UU.
No obstante, nos hemos encontrado con que casi todos estos pacientes, incluyendo algunos de los que han sufrido una trayectoria en descenso, colaboraron totalmente con nosotros en todos los aspectos posibles. Muchos de ellos interactuaron, no sólo a través
de Internet, de los medios de comunicación, etc. sino también con el NIH de EE. UU, solicitándoles que adopten nuestro protocolo en todos aquellos casos de tumor cerebral.
En lo que respecta a los posibles mecanismos de acción de los medicamentos se ofrecen detalles en otra parte del libro (Sen Pathak et al, 2003); sin embargo, en la actualidad, estamos llevando a cabo un estudio observacional de las citoquinas con el fin de hallar pistas además del probado cambio telomérico que se produce en los niveles genéticos (Sen Pathak et al, 2003).
De este modo, nuestros hallazgos indican claramente que este sencillo tratamiento médico con Ruta 6 y Fosfato Tricálcico es capaz de prevenir recidivas de tumores cerebrales en un importante número de pacientes. Este tratamiento es muy práctico al igual que económico y recomendamos sin ninguna reserva la aplicación del mismo a todos aquellos pacientes que padezcan tumor cerebral.
Referencias:
Banerji P, Banerji P. Intracraneal Cisticercosis: on effective treatment with alternative medicines. In Vivo. 2001; 15(2): 181-4.
Levin VA, Leibel SA, Gutin PH: Neoplasms of the central nervous system. In: DeVita VT Jr, hellman S, Rosenberg SA, eds.: Cancer: Principles and Practice of Oncology, 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001, pp 2100-60.
Parkin DM, Bray F, Ferlay J. et al.: Estimating the world cancer burden: Globacan, 2000. Int J Cancer 94 (2): 156-3, 2001.
Pathak S, Multani AS, Banerji P, Banerji P, Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes. A novel treatment for human brain cancer. Int J Oncol. 2003; 23(4): 975-82.
Nuestros planes futuros:
Hoy en día es tamos estudiando el efecto que los inmunomoduladores tienen sobre los tumores cerebrales así como sus modelos cambiantes durante el tratamiento con nuestros medicamentos. No obstante, nuestros planes futuros se basan en descubrir cuál es el motivo exacto que en algunos casos conduce al fracaso al igual que proporcionar otra terapia alternativa en el caso de que este protocolo fallase. Ya hemos concluido nuestros primeros trabajos siguiendo esta línea y hemos observado que en aquellos casos fallidos un preparado de Naranja Amarga pude tener unos efectos asombrosos (patente en trámite); de este modo se consiguen resultados cada vez más exitosos.
Acerca de la Fundación de Investigación Homeopática PB (PBHRF):
Al relacionarse con tal cantidad de pacientes, los Drs. Banerji se encontraron, a menudo, con gente que se hallaba en una situación de extremo desamparo. Para estos pacientes resulta imposible tener acceso a tan costosos recursos de investigación como el TAC (tomografía axial computarizada), los MRIs (imágenes por resonancia magnética), el ECG (electrocardiogramas) o incluso someterse a pruebas de precio relativamente razonable como un análisis de sangre. Para ayudar a estas personas y también para conseguir que el tratamiento fuera más preciso, se optó por financiar estas pruebas patológicas. Así fue como en 1992 se fundó la Fundación de Investigación Homeopática PB.
PBHRF – Clínica y Fundación de Investigación
El propósito de esta Fundación es el de instaurar la Homeopatía como un modo de Medicina científico y eficaz. Esta Fundación brinda una exhaustiva asistencia sanitaria así como un establecimiento científico con el fin de otorgar a la Homeopatía el lugar que le corresponde como la medicina de las masas.
Investigación colaborativa
Dr. Jeffrey D. White, Dir. OCAAM, NCI, EE.UU y Dr. Prasanta Banerji, Dr. Jeffrey D.White, Dir. OCAAM Ejecutivo Fiduciario, PBHRF en el NCI, EE.UU. NCI, EE.UU, Dr. Prasanta Banerji, Ejecutivo Fiduciario, PBHRF, Dr. Patrip Banerji, Ejecutivo Fiduciario Adjunto, PBHRF curaron a pacientes con cáncer en Calcuta, India.
La Fundación de Investigación Homeopática PB tiene su base en Calcuta y, en la actualidad, colabora en trabajos de investigación con las siguientes instituciones de renombre en todo el mundo:
•
•
•
•
Universidad de Texas MD Anderson Cancer Center de Houston, EE. UU., acerca de la acción de los medicamentos homeopáticos sobre varios tipos de células cancerígenas como tumores cerebrales, de pulmón y cáncer de pecho, etc. Laboratorio del Catedrático de Patología y Director, Image Cytology Diagnosis Laboratory (Laboratorio de diagnóstico por imagen de citología). Univesidad de Texas MD Anderson Cancer Center de Houston sobre el Carcinoma broncogénico. Laboratorio del Director, Cancer Research Unit (Unidad de investigación del cáncer), VA Medical Center, Universidad de Kansas sobre el Cáncer de mama. Departamento de farmacología de la Anadolu University de Eskisehir en Turquía desde el año pasado investiga acerca de la acción que nuestros medicamentos específicos ejercen sobre distintos tipos de células tumorales.
También se está llevando a cabo un minucioso trabajo de investigación y miles de pacientes con cáncer se han beneficiado del tratamiento del Protocolo Banerji en las últimas cuatro décadas.
Los Drs. Banerji y el Dr. Jeffrey D. White con el Dr. Vinod Kochupillal, HOD, Oncología Médica, AIIMS, Nueva Deli
Trabajos de investigación presentados en los Foros Científicos Internacionales
Dr. Prasanta Banerji en la VII Conferencia Dr. Pratip Banerji en la VII Conferencia Internacional de Investigación Anticáncer, 2004, Internacional de Investigación Anticáncer, 2004, Corfu, Grecia. Corfu, Grecia.
Corfu – Tras cuatro décadas dedicadas a la investigación, el Dr. Prasanta Banerji & el Dr. Pratip Banerji presentaron sus exitosos artículos en diversas conferencias homeopáticas internacionales. La primera vez que EE. UU se interesó por sus trabajos de investigación, fue durante la V Conferencia Internacional de Investigación Anticáncer que tuvo lugar en Corfu, Grecia, en el año 1995. El impacto global se sintió de inmediato después de que los Drs. Banerji, los únicos médicos homeopáticos de entre 1200 médicos que asistieron a la conferencia en Grecia, presentaran 16 casos de regresión de tumor cerebral y su curación con medicamentos homeopáticos.
La Universidad de Texas MD Anderson Cancer Center de Houston – El departamento de medicina alternativa de EE. UU. realizó un seguimiento de los casos expuestos en Corfu a través de la realización de pruebas de laboratorio aplicando los medicamentos homeopáticos de los Drs. Banerji sobre células cancerígenas en la Universidad de Texas MD Anderson Cancer Center (MDACC) de Houston. El Dr. Sen Pathak, catedrático de Genética y Biología Celular de la Universidad de Texas MD Anderson Cancer Center de Houston, colaboró en esta investigación en equipo llevada a cabo por el PBHRF y el MDACC. El trabajo de investigación ya está terminado y publicado. Mediante estudios in vitro con nuestros medicamentos se han obtenido resultados excepcionales de destrucción de las células cancerígenas a la vez que se produce una activación de las células normales. El artículo “La Ruta 6 provoca, de manera selectiva, la muerte de las células cancerígenas del cerebro pero produce la proliferación de los linfocitos sanguíneos periféricos normales: un tratamiento novedoso contra el cáncer cerebral en humanos” fue publicado conjuntamente por S. Pathak, AS. Multan del Departamento de Genética Molecular, MD Anderson Cancer Center de Houston, EE. UU., en el número de octubre de 2003 de la Revista Internacional de Oncología.
El Instituto Nacional del Cáncer, NIH de EE. UU. - En la actualidad, las universidades americanas son líderes mundiales en cuanto a la investigación médica se refiere. Hoy en día, estas instituciones, debido a sus amplios recursos, ejercen un control sobre todas las tendencias futuras en tecnología médica. Una institución de este tamaño es el Instituto Nacional del Cáncer del gobierno de EE. UU. En 1991, lanzó su programa Best Case Series con el fin de buscar enfoques alternativos de cara al
tratamiento del cáncer así como apoyar futuros proyectos de investigación haciendo uso de las terapias que se identifican en este programa.
El Dr. Prasanta Banerji, Fundador y Ejecutivo Fiduciario, PBHRF, y el Dr. Pratip Banerji, Cofundador y Ejecutivo Fiduciario Adjunto, PBHRF, presentaron su programa Best Case Series ante el NCI en marzo de 1998. Los Drs. Banerji reunieron 12 casos; "no nuestros mejores casos", dijo el Dr. Pratip Banerji, "pero sí los más completos". Fue un examen retrospectivo de 12 casos de pacientes con varios tumores malignos, de los cuales 7 eran de cáncer de pulmón. El NCI dio por completa la serie en marzo de 1999. “Nuestro único presentarque el Best Case Seriesseesconvierta el de seguir una trayectoria positiva conpropósito el fin de al conseguir la Homeopatía en un medio eficaz y bien promocionado de tratamiento con medicina complementaria y alternativa", dijo el Dr. Prasanta Banerji. De todo esto se obtuvo como resultado un acuerdo, jamás conseguido con anterioridad, entre una institución sanitaria de EE. UU.
y una rama de la medicina alternativa para la investigación del tratamiento contra el cáncer. La carta que recoge este compromiso, firmada con PBHRF por la Oficina de Medicina Complementaria y Alternativa para el Cáncer (OCCAM) del Instituto Nacional del Cáncer con sede en EE. UU. y por el Instituto Nacional de Salud de Maryland, es la primera carta de este tipo que reconoce la importancia que tiene la Homeopatía en el tratamiento del cáncer de pulmón.
El Dr. Prasanta Banerji y el Dr. Pratip Banerji fueron invitados a exponer sus trabajos en la conferencia "Comprehensive Cancer Care, 2000" patrocinada por el Instituto Nacional de Cáncer (NCI) y el Centro Nacional para la Medicina Complementaria y Alternativa (NCCAM) del NIH, EE. UU. que tuvo lugar del 9 al 11 de junio de 2000 en Arlington, VA, EE. UU. La presentación del artículo “Tumores Malignos: Recuperación de la salud mediante Medicamentos homeopáticos” fue acogida con gran éxito por los allí presentes.
Nueva Deli, 2001. Indian Science Congress, Millennium - En 2000, el Dr. Prasanta Banerji y el Dr. Pratip Banerji fueron invitados para presentar la ponencia científica de la conferencia “Tratamiento homeopático de la Tuberculosis”. En la misma conferencia, el Dr. Pratip Banerji expuso otro de sus trabajos titulado: “Tumores malignos: Un enfoque homeopático” . A esta conferencia asistieron muchos de los más prestigiosos científicos de India y ambas presentaciones tuvieron una gran aceptación.
En número 2 del volumen 15, de 2001 de la revista In Vivo del Internacional Institute of Anticancer Research de Attili, Grecia se publicó un artículo escrito por los Drs. Prasant y Pratip Banerji titulado “Cisticercosis Intracraneal: Un tratamiento eficaz con medicinas alternativas.”
Bienvenida a nuevos colaboradores:
A pesar de que hoy en día existen muchos colaboradores tanto dentro como fuera de nuestro país, siempre damos la bienvenida a nuevos colaboradores con el fin de perfeccionar cada vez más nuestro protocolo.
Perfiles:
Dr. Prasanta Banerjji, Fundador y Ejecutivo Fiduciario, PBHRF
PRASANTA fue el segundo hijo del Dr. Pareshnath Banerji. Aprobó su I.SC en el Vidyasagar Collage de Calcuta y después estudió en el INSTITUTO DE HOMEOPATÍA de Mihijam. Tras obtener su título en el Instituto en 1956 se convirtió en un todo un doctor y realizó prácticas en la clínica de s u padre en Mihijam, Bihar. Alrededor de 1958 pensó que si ampliaba su campo de actuación tendría más posibilidades de utilizar sus conocimientos homeopáticos por todo el país y beneficiar a la población ingente para que tuvieran la oportunidad de conseguir medios de tratamiento más económicos con el fin de curar sus enfermedades. Pensó en Calcuta como lugar para establecer su consultorio. El Dr. Prasanta Banerji se trasladó a Calcuta en 1958 donde fundó su clínica. En 1986, creó una segunda clínica debido a la cantidad de trabajo que tenía.
El Dr. Prasanta Banerji inculcó la misma fórmula que introdujo su padre el Dr. Pareshnath, la modificó y la mejoró convirtiéndola en un método de tratamiento concreto otorgando claridad y cordialidad a la Homeopatía. Hizo que la Homeopatía fuera fácil de aprender y de practicar, de este modo, la desmitificó. Esto permitió una duplicación en la ciencia. Debido a sus exclusivos esfuerzos a este respecto, el establecimiento científico moderno finalmente ha reconocido y aceptado el protocolo de tratamiento Banerji mediante el uso de medicamentos homeopáticos dentro de la corriente dominante de asistencia médica.
Dr. Pratip Banerji, Cofundador y Ejecutivo Fiduciario Adjunto, PBHRF
El Dr. Pratip Banerji pertenece a al cuarta generación de homeópatas de la familia; realizó su postgrado en Homeopatía Clásica en el London College. Tras finalizar su postgrado, Pratip fue invitado a comparecer ante el Consejo del Secretario británico de Médicos Complementarios (British Registrar of Complementary Physicians), y aceptó la invitación. Después recibió una carta del Consejo pidiéndole la dirección del lugar dónde le gustaría establecer su consultorio en el Reino Unido con el fin de poder enviarle pacientes. Pero Pratip regresó a India para establecer su propio consultorio en Calcuta y seguir los pasos de su padre para servir así a sus compatriotas. El Dr. Pratip Banerji introdujo un enfoque científico así como unos principios internacionales que permitieran la verificación de sus datos de investigación. Él inició el proceso de acumulación de información y documentación de acuerdo con los más
rigurosos principios internacionales. Esto ha hecho que la comunidad científica internacional aceptara su investigación. Su visión en cuanto al futuro de la Homeopatía ha animado enormemente a la PBHRF ha realizar colaboraciones de investigación con los principales centros científicos internacionales, de este modo, la homeopatía tiene un lugar seguro en las corrientes dominantes de las plataformas médicas internacionales.
NUEVO PROTOCOLO (6/7/07)
The Banerji Protocol ~ A New Horizon in Medicine …by Prasanta & Pratip Banerji of The PBH Research Foundation, India.
Introduction
The role and efficacy of Homeopathic medicines, on treatment of malignant tumors is largely unknown and unproven so far. Homeopathic therapy is mainly used for supportive cancer
care only and some have advised for an integration of this therapy with conventional methods. However, in a study done by Sharples et al in 2003, it was found that orthodox medicine is not meeting the needs of some patients and that Complementary and Alternative Medicine (CAM) may wholly or partly substitute for conventional medicines. Most patients indicated their problem had improved with Complementary and Alternative Medicine (CAM).
Homeopathic medicines are produced using various plant extract, salts, snake venoms, metals etc. and then by diluting the extracted mother tincture or the crude materials/ solutions as per homeopathic methods, which when ingested by healthy volunteers produce symptom complexes that mimic various diseases. These solutions are serially diluted and succussed until the desired potency is produced.
Classical Homeopathy has no specific remedy for any disease by name, but it has specificity for each individual case of disease. This approach of treating patients on the basis of symptoms only, is basically a must in long standing chronic diseases, and changes from patient to patient. A specific drug cannot be used for a specific disease. In general, when a Homeopathic Physician examines a patient, only a few medicines come toFinally his mind. groupasofamedicines exhibitsexperience similar symptoms proving. onlyThis one small is selected result of practical and thison procedure requires a long time. In an interesting study done by Becker-Witt et al in 2004, it was shown that a typical homeopathic initial consultation took 117 +/- 43 minutes for each adult patient and 86 +/- 36 minutes for each child patient.
Ours is a new method of treatment. Specific medicines are prescribed for specific diseases. Diseases are diagnosed using modern/state of the art methods. This is done because modern diagnostic approaches incorporate and help in the selection of medicines so that specific medicines can be easily prescribed for specific diseases.
With the passage of time and the availability of new diagnostic tools like Ultrasonography, MRIs, cancer markers and other advanced tests, we have been able to
further streamline the treatment protocols accurately. The efficiency of this streamlining is reflected by the encouraging results of our new method of treatment. We often combine two potentized medicines and use the combination in our practice. This combination of two potentized medicines, are made in a meaningful way based on years of clinical observations by us. They are combined for special advantages in treatment, so that the aggravation due to the medicines can be checked, side effects of the medicines abated, quick and uneventful recovery can be ensured in a much shorter time. Attempts to find out specific homeopathic medicine for a particular disease by many researchers in recent times also showed promising results such as the recent experiment on upper respiratory tract infections by Steinsbekk et al in 2004, clearly demonstrated that specific medicines were highly correlated with the homeopathically selected medicine. Similarly it was proved that homeopathic medicine Fluoric acid is a most effective preparation for radiation–induced itching in breast cancer patients. The National Institutes of Health (NIH), USA, was very interested in our research into various types of cancers and had asked us to produce records of our successes. This we had done by submitting a “Best Case Series” on Cancer to the National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI) at the NIH. On acceptance of our series, we were invited to present the same before the Cancer Advisory Panel for Complementary and Alternative Medicines in July 1999. As a result of our presentation, the NCI, USA, is at present devising a “Practice Outcomes Monitoring and Evaluation Systems Study for Bronchogenic Carcinoma” at our clinic in Kolkata, India, with a view to arrive at a protocol for treatment of these cases at institutions in the US. Therefore, scientific progress demands that we continuously carry on more and more experiments and keep observational records.
Along with the Professor of Cell Biology and Genetics, at the University of Texas MD Anderson Cancer Center, Houston, one paper has been published entitled “Ruta 6
selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer” in the International Journal of Oncology in October 2003 where our method of treatment with Ruta and Calcarea Phosphorica was followed with excellent results.
In our observation for the last 30 years, these medicines have the definite power to reduce and cure Intracranial SOL. It may be interesting to note that our claims with regard to the action of these medicines have been successfully vindicated in vitro. These slides show Metaphases from control and Ruta 6-treated MGR-one human brain cancer cells showing mitotic catastrophe:
A, normal metaphase spread from a control culture;
B, endo-re-duplicated partial metaphase spread showing dicentrics, chromatid breaks, and tri-radial configurations; and
C, an endoreduplicated metaphase with extensive chromosome fragmentations from Ruta-treated cultures. These slides show FISH (Fluorescent in-situ Hybridization) preparations of interphase cells from a human B-lymphoid cell line and MGR-one brain cancer either untreated or treated with Ruta 6 + Ca3(PO4)2 are stained with DAPI for DNA (blue), and telomeric DNA labeled with rhodamine (red).
B-lymphoid control cells (A)
and Ruta 6-treated cells (B) both show no reduction in telomeric signals.
Untreated control (C)
and Ruta-treated (D) … human brain cancer cells show significant difference in telomeric signals. Large nuclei from Ruta-treated cells show reduced telomeric signals. All microphotographs were taken at the same magnification. Both in vivo and in vitro results showed induction of survival-signaling pathways in normal lymphocytes and induction of death-signaling pathways in brain cancer cells. Cancer cell death was initiated by telomere erosion and completed through mitotic catastrophe events. We proposed that Ruta in combination with Ca3(PO4)2 could be used for effective treatment of brain cancers, particularly glioma. Of interest in this context is the fact that the brain tumor community in the US has shown an immense response to this protocol Weknowledge all know that patients suffering from serious diseases often acquireofa treatment. good deal of about their diseases. Lately, we have been receiving 60 to 70 mails a day from patients all over the world who have found the paper on Ruta and in an uncontrolled manner have started taking the medicines themselves. When after 3 to 4 months of treatment, they find that their tumor has regressed or become static, they contact us to fine tune the treatment for them.
Some have even gone so far as to set up user groups on the internet which are showing remarkable results. One such group is run by Mr. Alex Fidelibus and can be accessed on the projected URL: “http://health.groups.yahoo.com/group/Ruta6/”
Collaborative research work on Bronchogenic carcinoma is also going on in the laboratory of the Professor of Pathology and Director, Image Cytology Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center in Houston, on
breast cancers in the laboratory of the Director, Cancer Research Unit, VA Medical Center, University of Kansas Medical Center, and in the Department of Pharmacology at the Anadolu University in Eskisehir in Turkey on the action of our specific medicines on different brain tumor cell lines since the last one and a half years. 21% 3638 34% 5890 26% 4504 19% 3292 We have treated thousands of cancer patients in the last four decades. Here we now highlight some outcome of our treatment in the recent past.
This Graph shows general outcome of treatment of 17,324 cancer patients from 1990 to 2005 at our clinics. In 19% cases the malignant tumors were completely regressed which appeared to us very significant. In 21% cases they were static or improved after treatment. Over the last two years, there has been a spurt in the number of cancer cases visiting our clinics. It may be mentioned here that the above in-house figure is mainly based on those cases with complete documentation such as scan plates, biopsy slides and such, and the actual number of cancer cases under our treatment exceeds this figure. On an average about 1000 new cancer cases are registered in our clinics every month and in December 2006 we have treated 1136 new such cases. Thus presently it appears from all these findings that our new method of treatment with homeopathic medicines may be regarded as the future drug for cancer research and
treatment for the benefit of mankind.
A Presentation of Cases
From the vast number of cases under our treatment, we would like to present here, 7 cases which are considered to be incurable by any form of oral medication currently available in conventional medicine. In our research foundation we have treated these cases using only homeopathic medicines, and the following part of the presentation will show the results: Now let me show details of these cases: Esophageal Carcinoma – These two patients suffering from esophageal carcinoma were treated with the homeopathic medicine Condurango 30c, prepared from the plant Marsdenia condurango.
They were followed meticulously for several years and all srcinal documents, radiological plates and histology slides were kept for reference. There has been no evidence of recurrence or metastasis in either of them. The patients are now in normal health. Case No. 1
Mrs. C K, Female, aged 75 years was suffering for 3 months with difficulty in eating anything, return of food and drink on attempting to swallow, when she came to us for her treatment on 07.09.1995. Clinically the patient presented with severe dysphagia, an emaciated state of health, food pipe fitted jejunostomy that was done on 21.08.1995.
X-ray (Barium swallow of oesophagus) done on 19.08.1995 “…(Patient was too sick to
stand and swallow Barium at the time of X-ray)…shows gross filling defect at mid and lower 1/3rd –MALIGNANT NEOPLASM”.
Biopsy done on 28.08.1995 showed “…features suggestive of Squamous Cell Carcinoma”.
After undergoing treatment from us with the medicine Condurango 30c 2drops twice daily, the patient is asymptomatic and keeping alright. The jejunostomy was removed
some time after the start of our treatment when the patient was found to have recovered from her dysphagia.
Post treatment repeat X-ray barium swallow done on dated 12.10.1995 shows “…There is no filling defect in oesophagus”.
We are still reviewing the case every six months but there has been no recurrence. She is still living in good health.
Case No. 2
Mr. S D, male, aged 75 years was suffering for 2 months with difficulty in swallowing food, heartburn and belching, when he came to us for his treatment on 16.12.1996. Clinically the patient presented with dysphagia, heartburn and belching.
Endoscopy done on 29.11.1996 shows “…GE junction at 40cm. At 18 cm. is a growth extending upto 22cm. causing luminal narrowing”.
“…section shows moderately differentiated Squamous Cell Carcinoma”.
After undergoing treatment from us with the medicine Condurango 30c 2 drops twice daily, Now the patient is feeling much better. He is keeping good health and does not complain of dysphagia any more.
Post treatment barium swallow X-ray of oesophagus dated 12.07.1997 shows “… there is considerable improvement in the patency of the oesophagus”.
All plates together There were no complications during treatment. We are still reviewing the case every six months but there has been no recurrence. The Medicine
(Picture of Condurango plant) The botanical name of Condurango is Marsdenia condurango under the family Asclepiadaceae. Homeopathic medicines are produced from the bark and the medicines used by us were procured from reputed Homeopathic medicine manufacturers.
(Condurango chart) It is very difficult to explain the action of Condurango and how it
helps in the regression of esophageal tumors. Condurango contains large amounts of tannins. Tannins (commonly referred to as tannic acid) are water-soluble plant polyphenols comprising a heterogeneous group of compounds. An increasing body of experimental evidence indicates that tannins exert anti-carcinogenic activity and can inhibit the proliferation of cancer cells and induce apoptosis. Tannins of Terminalia catappa, which is a folk medicine, can prevent lipid peroxidation, superoxide formation and have free radical scavenging activities. In these ways they can prevent cancer. It has also been observed that tannic acid dietary intake in low doses can produce a strong chemo-protective activity against spontaneous hepatic neoplasm development in C3H male mice, most probably through anti-promoting mechanisms. Considering all these facts it appears that tannins of Condurango prevents development of cancer by antipromoting mechanisms, free radicals scavenging, decreasing lipid peroxidation and superoxide formation. After development of cancer, tannins of Condurango can initiate apoptotic mechanisms in the tumor cells and thereby produce a regression in the tumor. Thus our findings indicate that Condurango is a medicine that can be used with reasonable confidence in the treatment of esophageal carcinoma. Intracranial Space Occupying Lesions
Incidence of tumors the100,000 Brain, ofpopulation. its meningeal covering, the tumors spinal cord ranges from 11 to 19ofper About one halfand of of brain are primary lesions derived from neurons, glia or their supporting meningo-vascular structures. The remainders are metastatic lesions. As per traditional methods, treatments of brain tumors include maintenance medical therapy, surgery, radiation therapy, chemotherapy and immuno-therapy. In many cases, surgical removal of the tumor is impossible, in such cases, sometimes partial resection is effected. Response to radiotherapy and chemotherapy is poor in many cases, and in a good percentage of cases their administration in contraindicated. There are recurrences in many cases and good many cases show poor prognosis. In our Research Foundation, brain tumor cases are treated successfully with Homeopathic medicines. longsubsequently clinical experience, wecomplete could give relief to aInlarge percentage of cases, someInofour which exhibited regression. this presentation a study of 2 cases treated by us have been offered utilizing all medical reports and information kept documented over the years, including CT scans before and after treatment. The cases have been treated by the medicines Ruta graveolens 6c and Calcarea Phosphorica 3x. Case No. 3
F.Y, female, aged 27 years in December 1990, was suffering for 4 years with occasional attack of headaches (since 1986). She had severe attack of headache worse on the left side on 17th Dec 1990 with swoon and hazy vision when she came to us for her treatment on 29th Dec 1990. Clinically the Patient presented with haziness of vision, pain and weakness of the right side.
C.T. Scan of Brain dated 25.12.1990 – showed “The most significant abnormality is the presence of a mixed attenuating (hypo and hyperdense) well circumscribed mass at supraseller and intra-seller region producing marked expansion of the sella slightly more on left side. The fairly large mass measures about 2.2 cms in AP, 3.54 cms in transverse and 3.37 cms vertically as maximum dimensions. ?Craniopharyngioma, ?? Pituitary macroadenoma”.
After undergoing treatment from us with the medicines Ruta graveolens 6c and Calcarea Phosphorica 3x, Haziness of vision improved from the first month of the commencement of the treatment and vision has been completely restored now. Pain and weakness of the right arm completely recovered. She is now healthy and normal and enjoying life.
C.T. Scan of Brain dated 27th April 1992 - “Follow up case of a fairly large intrasellar mass with predominantly suprasellar extension now showing complete disappearance of the inhomogenously enhancing mass leaving behind normal appearances of the Pituitary gland and suprasellar cistern, since the last scan done on 25th Dec 1990”.
(Both Scans together) There were no complications during treatment. The husband of the patient visited us at the clinic on 30.11.1999. From him, we have learnt that the
patient is keeping well and he has promised to bring her for a CT scan at the earliest possible. Case 4
AA aged 60years, married gentleman came to us on 03.08.2004 and presented with gradual weakness of the left side of the body and limbs; Sleeplessness; Irritability and easy anger since 2 months. Before coming to us as per his initial observations,
C.T. Scan of Brain done on dated 28.07.2004 …. Impression: “…Multicentric Glioma….”
Stereotactic biopsy done on 29.07.2004… from right internal capsule – “…High grade neoplasm ... Glioma.” C.M.C. Hospital Vellore’s report on 29.07.2004…Suggestive of “Corpus collosum and right parietal periventricular high grade Glial Neoplasm?”
After undergoing treatment from us with the medicines Ruta 6c two doses a day, Calcarea Phosphorica 3X two doses a day, his all clinical symptoms were gone within 7-8 months. Till now patient is leading a trouble free, normal life but still continuing his medication.
C.T. Scan of Brain (Plain & Contrast Study) done on 16.04.2005 shows “…Hypodense areas and calcification in right frontal region. As compared to previous C.T. scan of
Brain done on 21.07.2004, the mass has almost resolved.”
– All plates together There were recurrent boils during treatment. We are still reviewing the case every six months but there has been no recurrence.
(Ruta action chart) Rutin, the active ingredient of Ruta, is known for its anti-oxidant and anti-inflammatory activities and also for reducing oxidative damage in a rodent model. In addition, Ruta is also known to protect from DNA strand breaks and to prevent
mutagenesis. Calcium phosphate activates phospholipase, which cleaves phosphalidylinositol biphosphate, a membrane bound molecule that activates protein kinase C. Thus one may consider these aspects for a possible explanation of such effects. Now I shall present two cases of bronchogenic carcinoma which were treated by us with very good results: Case No. 5
M. K. S., 47 years came to the clinic on 30th November 1994. He was suffering from chest pain with severe cough along with loss of weight since last three months. On examination restricted respiratory movement on the left side with few localized crepitations were present in the upper part of the left chest. Following investigations were done:
Chest X-ray dated 18.11.1994 showed “…there is a well-defined large soft tissue density mediastinal mass in the left upper mediastinum…the lung fields are well expanded. Area of consolidation is seen in the left upper lobe.”
C.T. Scan of chest dated 19.11.1994 shows “ There is a 8.0 cm x 6.4 cm well defined soft tissue mass...in upper mediastinum in left side…with air space consolidation of adjacent left upper lobe.”
C.T. Guided FNAC of mediastinal mass dated 24.11.1994 showed “…malignant tumor.”
X-ray dated 31.01.1995
X-ray dated 05.07.1995
X-ray dated 09.01.1996
(NCI Slide 1)
(NCI Slide 2) In the University of Texas MD Anderson Cancer Center Houston, it was described as a diagnosed case of Malignant Neoplasm. According to TNM classification of the tumor in this case, the growth was T2, N1, M0 – Stage II, if it was a case of metastasis from an unknown primary, then it would be staged at Stage IV.
After undergoing treatment from us with the medicines Kali Carbonicum 200c 2 drops thrice in a week and Ferrum Phosphoricum 3x 2 tablets twice daily, Patient is now asymptomatic and living his normal life.
Chest X-ray was done on several occasions last on 07.01.1999, which shows that there has been complete resolution of the mediastinal tumor. There were no complications during treatment.
– All plates together We are still reviewing the case every six months but there has been no recurrence. Case No. 6
Mrs. BM, female, aged 77 years was suffering for 3 months with loss of weight, anorexia, nausea, vomiting and chest pain, when she came to us for her treatment on 12.09.1994. Clinically the patient presented with loss of weight, anorexia, nausea, vomiting, chest pain with restricted movement of the chest wall in the right side, increased vocal fremitus and moderate crepitations.
X-ray chest (PA view) dated 27.12.1994 shows “…homogeneous triangular opacity of consolidation is seen in right mid zone”.
CT Scan of chest dated 09.01.1995 shows “…dense irregular lobulated mass with shaggy margins are seen in right upper lobe and lateral segment of lateral middle lobe.”
CT guided FNAC from right lung mass dated 09.01.1995 “ carcinoma lung (small cell type)”.
X-ray Chest on 09.01.1995 shows “…radio-opacity is seen in right upper and middle zone…”
X-ray Chest dated 24.03.1995
(NCI Slide 1)
(NCI Slide 2) In MD Anderson Hospital Houston, Texas it was described as a diagnosed case of Malignant Neoplasm Consistent With Non-Small Cell Carcinoma According to TNM classification of tumor in this case the growth was T (8.0cm x 6.4cm) N1M0 Stage III.
After undergoing treatment from us with the medicines Kali Carbonicum 200c 2 drops thrice in week and Ferrum Phosphoricum 3x 2 tablets twice daily. Patient is now asymptomatic and keeping all right.
Chest X-rays done on several occasions last on 19.12.1998, which show that there has been complete resolution of lung lesion. There were no complications during treatment.
– All plates together It is very difficult at present to explain how Kali Carbonicum can regress Bronchogenic carcinoma, however carcinogens in tobacco smoke e.g. NNK stimulates potassium channel in different tissues, including lung. Again ATP-sensitive potassium channel openers have been proven to be involved in protection of damaged lung tissue. Thus, Kali Carbonicum may act through these pathways. Case No 7. Osteogenic Sarcoma.
M L M, male, aged 8 years was suffering for 5 to 6 months with swelling in left knee and difficulty in flexing the knee, when he came to us for his treatment on 18th July 2003. Clinically the Patient presented with a non tender, firm to hard swelling over the left knee joint.
X-ray of left knee joint dated 5th June 2003 showed “…a well defined eccentric lesion in metaphyses with sclerosis at edges - ? fibrous cortical defect/aneurismal bone cyst/lymphoma…”
The child underwent Histopathological examination of the swelling and the report dated 12th June 2003 showed “…Section shows histology of a high grade sarcomatous lesion showing many mitotic figures…Poorly differentiated sarcomatous lesion…” At that time the parents of the child were advised at the Chittaranjan National Cancer Institute, Kolkata, to allow immediate “…above the lesion amputation…” of the affected leg.
After undergoing treatment from us with the medicines Symphytum 200c two doses a
day, Calcarea Phosphorica 3X two doses a day and Carcinosin 30c one dose every alternate day, the swelling gradually subsided and now the architecture of the knee has completely returned to normal. Patient is now asymptomatic and living his normal life.
X-ray dated 16th December 2003 “…reveals gross healing at osteolytic area...”
Last X-ray dated 14th August 2004 showed “…remineralization seen at the lower third of left femur...”
All slides together. There were no complications during treatment. In this lecture I have presented only seven proved malignant tumor cases who were regressed following treatment with specific homeopathic medicines - Kali Carbonicum and Ferrum Phosphoricum for bronchogenic carcinoma, Condurango for oesophageal carcinoma, Ruta and Calcarea Phosphorica for brain tumors and Symphytum for the Osteogenic Sarcoma. Most of these cases of were followed found normal years. in Wemany have studied thousands similar casesup andand promising resultseven haveafter beenfive obtained instances.
No presentation can be complete if we do not give tribute to our team of Doctors and accessory staff who help us to run our clinics….
Thank you for you
ABREVIATURAS AP – antero posterior CMC – colegio médico cristiano ECG - electrocardiograma MDACC - MD Anderson Cancer Center MIR – imágenes por
resonancia magnética
NCCAM - Centro Nacional para la NCI - Instituto Nacional del
Medicina Complementaria y Alternativa
Cáncer
NIH - Institutos Nacionales de la Salud OCCAM - Oficina de
Medicina Complementaria y Alternativa para el Cáncer
PBHRF – Fundación de Investigación Homeopática Prasanta Banerji TAC – Tomografía Axial
Computarizada
NUEVO PROTOCOLO (6/7/07)
The Banerji Protocol ~ A New Horizon in Medicine …by Prasanta & Pratip Banerji of The PBH Research Foundation, India.
Introduction
The role and efficacy of Homeopathic medicines, on treatment of malignant tumors is largely unknown and unproven so far. Homeopathic therapy is mainly used for supportive cancer
care only and some have advised for an integration of this therapy with conventional methods. However, in a study done by Sharples et al in 2003, it was found that orthodox medicine is not meeting the needs of some patients and that Complementary and Alternative Medicine (CAM) may wholly or partly substitute for conventional medicines. Most patients indicated their problem had improved with Complementary and Alternative Medicine (CAM).
Homeopathic medicines are produced using various plant extract, salts, snake venoms, metals etc. and then by diluting the extracted mother tincture or the crude materials/ solutions as per homeopathic methods, which when ingested by healthy volunteers produce symptom complexes that mimic various diseases. These solutions are serially diluted and succussed until the desired potency is produced.
Classical Homeopathy has no specific remedy for any disease by name, but it has
specificity for each individual case of disease. This approach of treating patients on the basis of symptoms only, is basically a must in long standing chronic diseases, and changes from patient to patient. A specific drug cannot be used for a specific disease. In general, when a Homeopathic Physician examines a patient, only a few medicines come to his mind. This small group of medicines exhibits similar symptoms on proving. Finally only one is selected as a result of practical experience and this procedure requires a long time. In an interesting study done by Becker-Witt et al in 2004, it was shown that a typical homeopathic initial consultation took 117 +/- 43 minutes for each adult patient and 86 +/- 36 minutes for each child patient.
Ours is a new method of treatment. Specific medicines are prescribed for specific diseases. Diseases diagnosed using modern/state the help art methods. This is done because modernare diagnostic approaches incorporateofand in the selection of medicines so that specific medicines can be easily prescribed for specific diseases.
With the passage of time and the availability of new diagnostic tools like Ultrasonography, MRIs, cancer markers and other advanced tests, we have been able to further streamline the treatment protocols accurately. The efficiency of this streamlining is reflected by the encouraging results of our new method of treatment. We often combine two potentized medicines and use the combination in our practice. This combination of two potentized medicines, are made in a meaningful way based on years of clinical observations by us. They are combined for special advantages in treatment, so that the aggravation due to the medicines can be checked, side effects of the medicines abated, quick and uneventful recovery can be ensured in a much shorter time. Attempts to find out specific homeopathic medicine for a particular disease by many researchers in recent times also showed as clearly the recent experiment on upper respiratory tract infections by promising Steinsbekkresults et al insuch 2004, demonstrated that specific medicines were highly correlated with the homeopathically selected medicine. Similarly it was proved that homeopathic medicine Fluoric acid is a most effective preparation for radiation–induced itching in breast cancer patients. The National Institutes of Health (NIH), USA, was very interested in our research into various types of cancers and had asked us to produce records of our successes. This we had done by submitting a “Best Case Series” on Cancer to the National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI) at the NIH. On acceptance of our series, we were invited to present the same before the Cancer Advisory Panel for Complementary and Alternative Medicines in July 1999. As a result of our presentation, the NCI, USA, is at present devising a “Practice Outcomes Monitoring and Evaluation Systems Study for Bronchogenic Carcinoma” at our clinic in Kolkata, India, with a view to arrive at a protocol for treatment of these cases at institutions in the US. Therefore, scientific progress demands that we continuously carry on more and more experiments and keep observational records.
Along with the Professor of Cell Biology and Genetics, at the University of Texas MD Anderson Cancer Center, Houston, one paper has been published entitled “Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer” in the International Journal of Oncology in October 2003 where our method of treatment with Ruta and Calcarea Phosphorica was followed with excellent results.
In our observation for the last 30 years, these medicines have the definite power to reduce and cure Intracranial SOL. It may be interesting to note that our claims with regard to the action of these medicines have been successfully vindicated in vitro. These slides show Metaphases from control and Ruta 6-treated MGR-one human brain cancer cells showing mitotic catastrophe:
A, normal metaphase spread from a control culture;
B, endo-re-duplicated partial metaphase spread showing dicentrics, chromatid breaks, and tri-radial configurations; and
C, an endoreduplicated metaphase with extensive chromosome fragmentations from Ruta-treated cultures. These slides show FISH (Fluorescent in-situ Hybridization) preparations of interphase cells from a human B-lymphoid cell line and MGR-one brain cancer either untreated or treated with Ruta 6 + Ca3(PO4)2 are stained with DAPI for DNA (blue), and telomeric DNA labeled with rhodamine (red).
B-lymphoid control cells (A)
and Ruta 6-treated cells (B) both show no reduction in telomeric signals.
Untreated control (C)
and Ruta-treated (D) … human brain cancer cells show significant difference in telomeric signals. Large nuclei from Ruta-treated cells show reduced telomeric signals. All microphotographs were taken at the same magnification. Both in vivo and in vitro results showed induction of survival-signaling pathways in normal lymphocytes and induction of death-signaling pathways in brain cancer cells. Cancer cell death was
initiated by telomere erosion and completed through mitotic catastrophe events. We proposed that Ruta in combination with Ca3(PO4)2 could be used for effective treatment of brain cancers, particularly glioma. Of interest in this context is the fact that the brain tumor community in the US has shown an immense response to this protocol of treatment. We all know that patients suffering from serious diseases often acquire a good deal of knowledge about their diseases. Lately, we have been receiving 60 to 70 mails a day from patients all over the world who have found the paper on Ruta and in an uncontrolled manner have started taking the medicines themselves. When after 3 to 4 months of treatment, they find that their tumor has regressed or become static, they contact us to fine tune the treatment for them.
Some have even gone so far as to set up user groups on the internet which are showing remarkable results. One such group is run by Mr. Alex Fidelibus and can be accessed on the projected URL: “http://health.groups.yahoo.com/group/Ruta6/”
Collaborative research work on Bronchogenic carcinoma is also going on in the laboratory of the Professor of Pathology and Director, Image Cytology Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center in Houston, on breast cancers in the laboratory of the Director, Cancer Research Unit, VA Medical Center, University of Kansas Medical Center, and in the Department of Pharmacology at the Anadolu University in Eskisehir in Turkey on the action of our specific medicines on different brain tumor cell lines since the last one and a half years. 21% 3638 34% 5890 26% 4504 19% 3292 We have treated thousands of cancer patients in the last four decades. Here we now highlight some outcome of our treatment in the recent past.
This Graph shows general outcome of treatment of 17,324 cancer patients from 1990 to 2005 at our clinics. In 19% cases the malignant tumors were completely regressed which appeared to us very significant. In 21% cases they were static or improved after treatment. Over the last two years, there has been a spurt in the number of cancer cases visiting our clinics. It may be mentioned here that the above in-house figure is mainly based on those cases with complete documentation such as scan plates, biopsy slides and such, and the actual number of cancer cases under our treatment exceeds this figure. On an average about 1000 new cancer cases are registered in our clinics every month and in December 2006 we have treated 1136 new such cases. Thus presently itmedicines appears from findings our drug new method of research treatmentand with homeopathic may all be these regarded as thethat future for cancer
treatment for the benefit of mankind.
A Presentation of Cases
From the vast number of cases under our treatment, we would like to present here, 7 cases which are considered to be incurable by any form of oral medication currently available in conventional medicine. In our research foundation we have treated these cases using only homeopathic medicines, and the following part of the presentation will show the results: Now let me show details of these cases: Esophageal Carcinoma – These two patients suffering from esophageal carcinoma were treated with the homeopathic medicine Condurango 30c, prepared from the plant Marsdenia condurango.
They were followed meticulously for several years and all srcinal documents, radiological plates and histology slides were kept for reference. There has been no evidence of recurrence or metastasis in either of them. The patients are now in normal health. Case No. 1
Mrs. C K, Female, aged 75 years was suffering for 3 months with difficulty in eating anything, return of food and drink on attempting to swallow, when she came to us for her treatment on 07.09.1995. Clinically the patient presented with severe dysphagia, an emaciated state of health, food pipe fitted jejunostomy that was done on 21.08.1995.
X-ray (Barium swallow of oesophagus) done on 19.08.1995 “…(Patient was too sick to
stand and swallow Barium at the time of X-ray)…shows gross filling defect at mid and lower 1/3rd –MALIGNANT NEOPLASM”.
Biopsy done on 28.08.1995 showed “…features suggestive of Squamous Cell Carcinoma”.
After undergoing treatment from us with the medicine Condurango 30c 2drops twice daily, the patient is asymptomatic and keeping alright. The jejunostomy was removed
some time after the start of our treatment when the patient was found to have recovered from her dysphagia.
Post treatment repeat X-ray barium swallow done on dated 12.10.1995 shows “…There is no filling defect in oesophagus”.
We are still reviewing the case every six months but there has been no recurrence. She is still living in good health.
Case No. 2
Mr. S D, male, aged 75 years was suffering for 2 months with difficulty in swallowing food, heartburn and belching, when he came to us for his treatment on 16.12.1996. Clinically the patient presented with dysphagia, heartburn and belching.
Endoscopy done on 29.11.1996 shows “…GE junction at 40cm. At 18 cm. is a growth extending upto 22cm. causing luminal narrowing”.
“…section shows moderately differentiated Squamous Cell Carcinoma”.
After undergoing treatment from us with the medicine Condurango 30c 2 drops twice daily, Now the patient is feeling much better. He is keeping good health and does not complain of dysphagia any more.
Post treatment barium swallow X-ray of oesophagus dated 12.07.1997 shows “… there is considerable improvement in the patency of the oesophagus”.
All plates together There were no complications during treatment. We are still reviewing the case every six months but there has been no recurrence. The Medicine
(Picture of Condurango plant) The botanical name of Condurango is Marsdenia condurango under the family Asclepiadaceae. Homeopathic medicines are produced from the bark and the medicines used by us were procured from reputed Homeopathic medicine manufacturers.
(Condurango chart) It is very difficult to explain the action of Condurango and how it
helps in the regression of esophageal tumors. Condurango contains large amounts of tannins. Tannins (commonly referred to as tannic acid) are water-soluble plant polyphenols comprising a heterogeneous group of compounds. An increasing body of experimental evidence indicates that tannins exert anti-carcinogenic activity and can inhibit the proliferation of cancer cells and induce apoptosis. Tannins of Terminalia catappa, which is a folk medicine, can prevent lipid peroxidation, superoxide formation and have free radical scavenging activities. In these ways they can prevent cancer. It has also been observed that tannic acid dietary intake in low doses can produce a strong chemo-protective activity against spontaneous hepatic neoplasm development in C3H male mice, most probably through anti-promoting mechanisms. Considering all these facts it appears that tannins of Condurango prevents development of cancer by antipromoting mechanisms, free radicals scavenging, decreasing lipid peroxidation and superoxide formation. After development of cancer, tannins of Condurango can initiate apoptotic mechanisms in the tumor cells and thereby produce a regression in the tumor. Thus our findings indicate that Condurango is a medicine that can be used with reasonable confidence in the treatment of esophageal carcinoma. Intracranial Space Occupying Lesions
Incidence of tumors the100,000 Brain, ofpopulation. its meningeal covering, the tumors spinal cord ranges from 11 to 19ofper About one halfand of of brain are primary lesions derived from neurons, glia or their supporting meningo-vascular structures. The remainders are metastatic lesions. As per traditional methods, treatments of brain tumors include maintenance medical therapy, surgery, radiation therapy, chemotherapy and immuno-therapy. In many cases, surgical removal of the tumor is impossible, in such cases, sometimes partial resection is effected. Response to radiotherapy and chemotherapy is poor in many cases, and in a good percentage of cases their administration in contraindicated. There are recurrences in many cases and good many cases show poor prognosis. In our Research Foundation, brain tumor cases are treated successfully with Homeopathic medicines. longsubsequently clinical experience, wecomplete could give relief to aInlarge percentage of cases, someInofour which exhibited regression. this presentation a study of 2 cases treated by us have been offered utilizing all medical reports and information kept documented over the years, including CT scans before and after treatment. The cases have been treated by the medicines Ruta graveolens 6c and Calcarea Phosphorica 3x. Case No. 3
F.Y, female, aged 27 years in December 1990, was suffering for 4 years with occasional attack of headaches (since 1986). She had severe attack of headache worse on the left side on 17th Dec 1990 with swoon and hazy vision when she came to us for her treatment on 29th Dec 1990. Clinically the Patient presented with haziness of vision, pain and weakness of the right side.
C.T. Scan of Brain dated 25.12.1990 – showed “The most significant abnormality is the presence of a mixed attenuating (hypo and hyperdense) well circumscribed mass at supraseller and intra-seller region producing marked expansion of the sella slightly more on left side. The fairly large mass measures about 2.2 cms in AP, 3.54 cms in transverse and 3.37 cms vertically as maximum dimensions. ?Craniopharyngioma, ?? Pituitary macroadenoma”.
After undergoing treatment from us with the medicines Ruta graveolens 6c and Calcarea Phosphorica 3x, Haziness of vision improved from the first month of the commencement of the treatment and vision has been completely restored now. Pain and weakness of the right arm completely recovered. She is now healthy and normal and enjoying life.
C.T. Scan of Brain dated 27th April 1992 - “Follow up case of a fairly large intrasellar mass with predominantly suprasellar extension now showing complete disappearance of the inhomogenously enhancing mass leaving behind normal appearances of the Pituitary gland and suprasellar cistern, since the last scan done on 25th Dec 1990”.
(Both Scans together) There were no complications during treatment. The husband of the patient visited us at the clinic on 30.11.1999. From him, we have learnt that the
patient is keeping well and he has promised to bring her for a CT scan at the earliest possible. Case 4
AA aged 60years, married gentleman came to us on 03.08.2004 and presented with gradual weakness of the left side of the body and limbs; Sleeplessness; Irritability and easy anger since 2 months. Before coming to us as per his initial observations,
C.T. Scan of Brain done on dated 28.07.2004 …. Impression: “…Multicentric Glioma….”
Stereotactic biopsy done on 29.07.2004… from right internal capsule – “…High grade neoplasm ... Glioma.” C.M.C. Hospital Vellore’s report on 29.07.2004…Suggestive of “Corpus collosum and right parietal periventricular high grade Glial Neoplasm?”
After undergoing treatment from us with the medicines Ruta 6c two doses a day, Calcarea Phosphorica 3X two doses a day, his all clinical symptoms were gone within 7-8 months. Till now patient is leading a trouble free, normal life but still continuing his medication.
C.T. Scan of Brain (Plain & Contrast Study) done on 16.04.2005 shows “…Hypodense areas and calcification in right frontal region. As compared to previous C.T. scan of
Brain done on 21.07.2004, the mass has almost resolved.”
– All plates together There were recurrent boils during treatment. We are still reviewing the case every six months but there has been no recurrence.
(Ruta action chart) Rutin, the active ingredient of Ruta, is known for its anti-oxidant and anti-inflammatory activities and also for reducing oxidative damage in a rodent model. In addition, Ruta is also known to protect from DNA strand breaks and to prevent
mutagenesis. Calcium phosphate activates phospholipase, which cleaves phosphalidylinositol biphosphate, a membrane bound molecule that activates protein kinase C. Thus one may consider these aspects for a possible explanation of such effects. Now I shall present two cases of bronchogenic carcinoma which were treated by us with very good results: Case No. 5
M. K. S., 47 years came to the clinic on 30th November 1994. He was suffering from chest pain with severe cough along with loss of weight since last three months. On examination restricted respiratory movement on the left side with few localized crepitations were present in the upper part of the left chest. Following investigations were done:
Chest X-ray dated 18.11.1994 showed “…there is a well-defined large soft tissue density mediastinal mass in the left upper mediastinum…the lung fields are well expanded. Area of consolidation is seen in the left upper lobe.”
C.T. Scan of chest dated 19.11.1994 shows “ There is a 8.0 cm x 6.4 cm well defined soft tissue mass...in upper mediastinum in left side…with air space consolidation of adjacent left upper lobe.”
C.T. Guided FNAC of mediastinal mass dated 24.11.1994 showed “…malignant tumor.”
X-ray dated 31.01.1995
X-ray dated 05.07.1995
X-ray dated 09.01.1996
(NCI Slide 1)
(NCI Slide 2) In the University of Texas MD Anderson Cancer Center Houston, it was described as a diagnosed case of Malignant Neoplasm. According to TNM classification of the tumor in this case, the growth was T2, N1, M0 – Stage II, if it was a case of metastasis from an unknown primary, then it would be staged at Stage IV.
After undergoing treatment from us with the medicines Kali Carbonicum 200c 2 drops thrice in a week and Ferrum Phosphoricum 3x 2 tablets twice daily, Patient is now asymptomatic and living his normal life.
Chest X-ray was done on several occasions last on 07.01.1999, which shows that there has been complete resolution of the mediastinal tumor. There were no complications during treatment.
– All plates together We are still reviewing the case every six months but there has been no recurrence. Case No. 6
Mrs. BM, female, aged 77 years was suffering for 3 months with loss of weight, anorexia, nausea, vomiting and chest pain, when she came to us for her treatment on 12.09.1994. Clinically the patient presented with loss of weight, anorexia, nausea, vomiting, chest pain with restricted movement of the chest wall in the right side, increased vocal fremitus and moderate crepitations.
X-ray chest (PA view) dated 27.12.1994 shows “…homogeneous triangular opacity of consolidation is seen in right mid zone”.
CT Scan of chest dated 09.01.1995 shows “…dense irregular lobulated mass with shaggy margins are seen in right upper lobe and lateral segment of lateral middle lobe.”
CT guided FNAC from right lung mass dated 09.01.1995 “ carcinoma lung (small cell type)”.
X-ray Chest on 09.01.1995 shows “…radio-opacity is seen in right upper and middle zone…”
X-ray Chest dated 24.03.1995
(NCI Slide 1)
(NCI Slide 2) In MD Anderson Hospital Houston, Texas it was described as a diagnosed case of Malignant Neoplasm Consistent With Non-Small Cell Carcinoma According to TNM classification of tumor in this case the growth was T (8.0cm x 6.4cm) N1M0 Stage III.
After undergoing treatment from us with the medicines Kali Carbonicum 200c 2 drops thrice in week and Ferrum Phosphoricum 3x 2 tablets twice daily. Patient is now asymptomatic and keeping all right.
Chest X-rays done on several occasions last on 19.12.1998, which show that there has been complete resolution of lung lesion. There were no complications during treatment.
– All plates together It is very difficult at present to explain how Kali Carbonicum can regress Bronchogenic carcinoma, however carcinogens in tobacco smoke e.g. NNK stimulates potassium channel in different tissues, including lung. Again ATP-sensitive potassium channel openers have been proven to be involved in protection of damaged lung tissue. Thus, Kali Carbonicum may act through these pathways. Case No 7. Osteogenic Sarcoma.
M L M, male, aged 8 years was suffering for 5 to 6 months with swelling in left knee and difficulty in flexing the knee, when he came to us for his treatment on 18th July 2003. Clinically the Patient presented with a non tender, firm to hard swelling over the left knee joint.
X-ray of left knee joint dated 5th June 2003 showed “…a well defined eccentric lesion in metaphyses with sclerosis at edges - ? fibrous cortical defect/aneurismal bone cyst/lymphoma…”
The child underwent Histopathological examination of the swelling and the report dated 12th June 2003 showed “…Section shows histology of a high grade sarcomatous lesion showing many mitotic figures…Poorly differentiated sarcomatous lesion…” At that time the parents of the child were advised at the Chittaranjan National Cancer Institute, Kolkata, to allow immediate “…above the lesion amputation…” of the affected leg.
After undergoing treatment from us with the medicines Symphytum 200c two doses a
day, Calcarea Phosphorica 3X two doses a day and Carcinosin 30c one dose every alternate day, the swelling gradually subsided and now the architecture of the knee has completely returned to normal. Patient is now asymptomatic and living his normal life.
X-ray dated 16th December 2003 “…reveals gross healing at osteolytic area...”
Last X-ray dated 14th August 2004 showed “…remineralization seen at the lower third of left femur...”
All slides together. There were no complications during treatment. In this lecture I have presented only seven proved malignant tumor cases who were regressed following treatment with specific homeopathic medicines - Kali Carbonicum and Ferrum Phosphoricum for bronchogenic carcinoma, Condurango for oesophageal carcinoma, Ruta and Calcarea Phosphorica for brain tumors and Symphytum for the Osteogenic Sarcoma. Most of these cases of were followed found normal years. in Wemany have studied thousands similar casesup andand promising resultseven haveafter beenfive obtained instances.
No presentation can be complete if we do not give tribute to our team of Doctors and accessory staff who help us to run our clinics….
Thank you for you El tratamiento de Ruta 6 está contraindicado con el vinagre y la vitamina C
